Etripamil (Cardamyst): A New Era in Acute SVT Management

Etripamil (Cardamyst): A New Era in Acute SVT Management

Etripamil represents the first major pharmacologic innovation for supraventricular tachycardia (SVT) in decades. Approved by the FDA in December 2025, etripamil offers a patient-controlled, intranasal option for the acute termination of paroxysmal supraventricular tachycardia (PSVT) in adults. Its approval marks a paradigm shift from hospital-based intravenous therapy to rapid at-home management.

Background: Why a New SVT Drug Was Needed

Paroxysmal SVT is a common arrhythmia characterized by sudden onset and termination of rapid regular tachycardia, most often due to AV nodal re-entrant tachycardia (AVNRT) or AV re-entrant tachycardia (AVRT).

Traditional acute management includes vagal maneuvers followed by intravenous adenosine or IV calcium channel blockers (verapamil, diltiazem) in the emergency department.

Limitations of existing therapies include:

• Need for IV access and hospital setting

• Significant hypotension with IV CCBs

• Patient anxiety and frequent ER visits

• No approved self-administered acute therapy

Etripamil was developed specifically to address these gaps.

What Is Etripamil?

Etripamil is a Class IV anti-arrhythmic agent belonging to the non-dihydropyridine calcium channel blocker family. Pharmacologically, it is related to verapamil and diltiazem but engineered for ultra-short action and intranasal delivery.

Key pharmacologic characteristics:

• Potent L-type calcium channel blockade

• Predominant effect on the AV node

• Very rapid onset of action

• Extremely short half-life

• Minimal systemic exposure

Mechanism of Action

Etripamil blocks L-type calcium channels within AV nodal tissue, leading to:

• Slowing of AV nodal conduction

• Increased AV nodal refractoriness

• Interruption of re-entrant circuits involving the AV node

This mechanism makes it effective for AV node–dependent PSVT while explaining why it is ineffective and contraindicated in atrial fibrillation, atrial flutter, and ventricular tachycardia.

Route of Administration and Dosing

One of the most transformative aspects of etripamil is its intranasal delivery system.

Dose and use:

• Route: Intranasal spray

• Adult dose: 70 mg per episode

• Administration: One spray in each nostril

• Timing: At onset of PSVT symptoms

• Repeat dosing: Only as specified in prescribing information

Intranasal delivery allows rapid systemic absorption via the nasal mucosa, bypassing first-pass metabolism and eliminating the need for IV access.

Clinical Benefits

Etripamil offers several clinically meaningful advantages:

Self-administration

Patients can treat PSVT episodes at home without immediate medical supervision.

Rapid onset

Designed to terminate PSVT quickly, often within minutes.

Ultra-short duration

Short half-life reduces prolonged hypotension or bradycardia.

Improved safety profile

Lower risk of sustained hypotension compared with IV calcium channel blockers.

Healthcare impact

Potential reduction in emergency department visits and healthcare costs.

Indications

Approved indication:

• Acute termination of paroxysmal supraventricular tachycardia (PSVT) in adults

Most effective in:

• AVNRT

• AVRT involving an accessory pathway with AV node participation

Not Indicated / Not Effective In

Etripamil should not be used in:

• Atrial fibrillation

• Atrial flutter

• Ventricular tachycardia

• Chronic suppression of SVT

Because its action is AV node–dependent, it does not control atrial arrhythmias with chaotic or macro–reentrant atrial activity.

Adverse Effects

Common side effects (usually mild and transient):

• Nasal irritation or discomfort

• Headache

• Facial flushing

• Mild dizziness

• Nausea

Rare but reported adverse effects:

• Transient hypotension

• Palpitations

• Shortness of breath

Due to its short half-life, most adverse effects resolve quickly without intervention.

Contraindications and Precautions

Avoid use in:

• Severe hypotension

• High-grade AV block without a pacemaker

• Known hypersensitivity to calcium channel blockers

Use caution in:

• Patients taking other AV nodal–blocking agents

• Pregnancy and breastfeeding (consult physician)

Patients must be educated to seek emergency care if:

• Symptoms do not resolve

• Diagnosis is uncertain

• Hemodynamic instability develops

Role in Clinical Practice

Etripamil is not a replacement for electrophysiology evaluation or catheter ablation in recurrent SVT, but it fills a critical gap between reassurance and emergency care. It empowers selected patients with a confirmed diagnosis of PSVT to manage acute episodes safely and rapidly.

Its approval represents a shift toward patient-centered arrhythmia care, similar to how self-injectable therapies transformed migraine and anaphylaxis management.

Conclusion

Etripamil (Cardamyst) is the first FDA-approved, self-administered intranasal therapy for acute PSVT. With rapid onset, ultra-short action, and a favorable safety profile, it represents a major advance in SVT management. Proper patient selection, education, and adherence to indications are essential to maximize benefit and ensure safety.

For more cardiology articles and infographics visit:

drmusmanjaved.com